Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_2
6
67%
Ph not_applicable
1
11%
Ph phase_1
2
22%

Phase Distribution

2

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
6(66.7%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(5)
Terminated(2)
Other(2)

Detailed Status

Completed5
Terminated2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
71.4%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (22.2%)
Phase 26 (66.7%)
N/A1 (11.1%)

Trials by Status

terminated222%
unknown222%
completed556%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_2

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

NCT00450983
completednot_applicable

Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

NCT00027443
unknownphase_2

Lymphocyte Therapy in Treating Patients With Kidney Cancer

NCT00002589
unknownphase_1

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

NCT00002482
completedphase_1

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

NCT00002572
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00450983Phase 2

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Terminated
NCT00027443Not Applicable

Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

Completed
NCT00002589Phase 2

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Unknown
NCT00002482Phase 1

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

Unknown
NCT00002572Phase 1

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

Completed
NCT00004022Phase 2

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Completed
NCT00004024Phase 2

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Completed
NCT00005852Phase 2

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Terminated
NCT00004482Phase 2

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9